Polymorph screening in early drug development serves to:

• A. Systematic evaluation of all possible solid forms (polymorphs, solvates, hydrates) to identify the most stable and soluble form, ensuring consistent performance and supply.
• B. Randomly selecting one solid form for development.
• C. Focus only on the anhydrous crystalline form.
• D. Polymorph screening is optional and rarely impacts formulation.

Answer: (A)

Polymorph screening focuses on systematically evaluating all possible solid forms a drug candidate can adopt, including polymorphs, solvates, and hydrates, to identify the form that offers the best combination of stability, solubility, and manufacturability. Different solid forms can dissolve at different rates, respond differently to humidity and temperature, and crystallize with varying ease during scale-up. By screening early, you pinpoint a form that delivers consistent therapeutic performance, reliable supply, and smoother formulation and regulatory development.

Choosing a form at random risks poor solubility or instability, which can compromise bioavailability or shelf life and create manufacturing and supply challenges. Limiting the focus to only the anhydrous crystalline form ignores other forms that might be more stable, more soluble, or easier to process. And treating polymorph screening as optional underestimates how much solid-form behavior can influence formulation strategy and patent/lifecycle considerations.